How protein modifications affect androgen receptor signaling in prostate cancer
Official title: Regulation of androgen receptor signaling in prostate cancer by protein arginine methylation
Funded at Dana-Farber Cancer Inst · NIH-11059872 · Data updated 2026-11-12
This study is looking at how certain proteins affect the way the androgen receptor works in advanced prostate cancer, especially when the cancer stops responding to usual hormone treatments, and it hopes to find new ways to combine existing therapies with new treatments to help patients facing this challenge.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | April 1, 2023 |
| Project end | March 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $536,161 |
| NIH project number | 5U01CA269505-03 |
| Project ID | NIH-11059872 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are men diagnosed with advanced prostate cancer, particularly those whose cancer has become resistant to hormonal therapies.
✕Less likely to help
Patients with early-stage prostate cancer or those not experiencing androgen resistance may not benefit from this research.
What this research studies
This research investigates the role of protein arginine methylation in regulating androgen receptor (AR) signaling in advanced prostate cancer. It aims to understand how specific proteins, PRMT1 and PRMT5, influence AR activity, particularly in cases where prostate cancer becomes resistant to standard hormonal therapies. By using advanced techniques like CRISPR/Cas9, the study will explore potential new treatment strategies that combine inhibitors of these proteins with existing AR antagonists. This approach could lead to more effective therapies for patients with castration-resistant prostate cancer.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that improve outcomes for men with advanced prostate cancer.
How similar studies have gone: Other research has shown promise in targeting androgen receptor signaling and protein modifications, indicating that this approach could be a meaningful advancement in treatment.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Viswanathan, Srinivas Raghavan — Dana-Farber Cancer Inst
- Study coordinator: Viswanathan, Srinivas Raghavan
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.